Skip to search formSkip to main contentSkip to account menu

NVP-BYL719

National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

BYL719

Broader (1)

Thiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 3596: Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX)
The cell cycle G1-restriction point is frequently deregulated in HR+ BC by alterations of cyclin D1 (CCND1), p16 (CDKN2A) or pRb… 
2018
2018
Abstract 3933: Circadian timing regimen for alpelisib (NVP-BYL719), a selective inhibitor of the class Ia PI3K isoform alpha to maximize therapeutic index
2017
2017
PI3Kα-selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is a highly malignant and metastatic pediatric cancer that arises from the skeletal muscle. Recent studies… 
2016
2016
Abstract LB-215: Combination studies using PI3K isoform-selective inhibitors in PTEN-deficient cancer cells
A large and growing body of evidence indicates that dysregulation of phosphoinositide 3-kinase (PI3K) pathway signaling activity… 
2015
2015
Abstract CT232: SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Background: Mutations in PIK3CA, the gene… 
2015
2015
Abstract 2670: BKM120 and BYL719 (PI3K inhibitors) sensitize estrogen receptor positive breast cancer cells to tamoxifen
Background: Tamoxifen is currently standard first line hormonal therapy for premenopausal estrogen receptor (ER) positive… 
2015
2015
Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
e14632 Background: Colorectal cancer (CRC) remains a leading cause of mortality and morbidity, despite developments in the… 
2014
2014
Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials
Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kamay have… 
2014
2014
NVP-BYL719, a novel PI3K-alpha selective inhibitor, overcomes acquired erlotinib resistance via upregulation of the PI3K/Akt/ mTOR pathway in pancreatic ductal adenocarcinoma
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with few treatment options. Epidermal growth factor receptor… 
2012
2012
Abstract 3743: NVP-BYL719, a selective inhibitor of the class Ia PI3K isoform alpha impairs angiogenesis and microvascular permeability.
Tumor blood vessels are distinctly abnormal in structure and function. When compared to normal vessels, they are enlarged… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)